LU90392I2 - Une combination comprenant du salmeterol facultativement sous la forme d'un sel pharmaceutiquement acceptable y compris le 1-hydroxy-2-naphtoate (xinafoate) et le propionate de fluticasone - Google Patents

Une combination comprenant du salmeterol facultativement sous la forme d'un sel pharmaceutiquement acceptable y compris le 1-hydroxy-2-naphtoate (xinafoate) et le propionate de fluticasone

Info

Publication number
LU90392I2
LU90392I2 LU90392C LU90392C LU90392I2 LU 90392 I2 LU90392 I2 LU 90392I2 LU 90392 C LU90392 C LU 90392C LU 90392 C LU90392 C LU 90392C LU 90392 I2 LU90392 I2 LU 90392I2
Authority
LU
Luxembourg
Prior art keywords
salmeterol
acceptable salt
fluticasone propionate
xinafoate
naphthoate
Prior art date
Application number
LU90392C
Other languages
English (en)
French (fr)
Inventor
James Barry Douglas Palmer
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27264677&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU90392(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB898920392A external-priority patent/GB8920392D0/en
Priority claimed from GB898923644A external-priority patent/GB8923644D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of LU90392I2 publication Critical patent/LU90392I2/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
LU90392C 1989-09-08 1999-04-26 Une combination comprenant du salmeterol facultativement sous la forme d'un sel pharmaceutiquement acceptable y compris le 1-hydroxy-2-naphtoate (xinafoate) et le propionate de fluticasone LU90392I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB898920392A GB8920392D0 (en) 1989-09-08 1989-09-08 Medicaments
GB898923644A GB8923644D0 (en) 1989-10-20 1989-10-20 Medicaments
SG166294A SG166294G (en) 1989-09-08 1994-11-18 Inhalation medicaments for treating respiratory disorders

Publications (1)

Publication Number Publication Date
LU90392I2 true LU90392I2 (fr) 1999-06-28

Family

ID=27264677

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90392C LU90392I2 (fr) 1989-09-08 1999-04-26 Une combination comprenant du salmeterol facultativement sous la forme d'un sel pharmaceutiquement acceptable y compris le 1-hydroxy-2-naphtoate (xinafoate) et le propionate de fluticasone

Country Status (20)

Country Link
EP (1) EP0416951B1 (en:Method)
JP (1) JP3042867B2 (en:Method)
AT (1) ATE99941T1 (en:Method)
BE (1) BE1003053A3 (en:Method)
CA (1) CA2024916C (en:Method)
CH (1) CH680983C9 (en:Method)
DE (2) DE19975040I2 (en:Method)
DK (1) DK0416951T3 (en:Method)
ES (1) ES2062392T3 (en:Method)
FR (1) FR2651677B1 (en:Method)
HK (1) HK18695A (en:Method)
HU (1) HU211272A9 (en:Method)
IE (1) IE65535B1 (en:Method)
IL (1) IL95590A (en:Method)
IT (1) IT1241996B (en:Method)
LU (1) LU90392I2 (en:Method)
NL (1) NL990012I2 (en:Method)
NZ (1) NZ235221A (en:Method)
PH (1) PH27594A (en:Method)
SG (1) SG166294G (en:Method)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270305A (en) 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
CA2123909C (en) * 1991-12-18 2002-10-01 Christer Carl Gustav Carling New combination of formoterol and budesonide
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
DE59904488D1 (de) 1998-11-13 2003-04-10 Jago Res Ag Muttenz Trockenpulver zur inhalation
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) 1999-03-03 1999-04-28 Novartis Ag Organic compounds
JP2003509359A (ja) 1999-09-11 2003-03-11 グラクソ グループ リミテッド プロピオン酸フルチカゾンの医薬製剤
JP2003518484A (ja) * 1999-12-24 2003-06-10 グラクソ グループ リミテッド サルメテロールおよびプロピオン酸フルチカゾンの医薬用エアゾル製剤
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6759398B2 (en) * 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
BRPI0113042B8 (pt) * 2000-08-05 2021-05-25 Glaxo Group Ltd composto da fórmula ou um seu solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica, método para o tratamento de um indivíduo humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para preparar um composto ou um seu solvato
FI20002216A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
EP1366025B1 (en) 2001-03-08 2007-06-27 Glaxo Group Limited Agonists of beta-adrenoreceptors
DE60224172T2 (de) 2001-03-22 2008-12-04 Glaxo Group Ltd., Greenford Formanilid-derivative als beta2-adrenorezeptor-agonisten
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
JP4446661B2 (ja) 2001-04-30 2010-04-07 グラクソ グループ リミテッド 抗炎症性の、17α位に環状エステル基を有するアンドロスタンの17β−カルボチオ酸エステル誘導体
PT2042168E (pt) 2001-09-14 2014-01-03 Glaxo Group Ltd Formulação de inalação compreendendo derivados de fenetanolamina para o tratamento de doenças respiratórias
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
US7258118B2 (en) 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
EP1757281A3 (en) * 2002-02-04 2009-07-15 Glaxo Group Limited Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
WO2003066033A1 (en) 2002-02-04 2003-08-14 Glaxo Group Limited Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
JP2005519110A (ja) * 2002-03-04 2005-06-30 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 新規なケイ皮酸塩、その調製方法及び医薬品としての使用
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
WO2004052374A1 (en) 2002-12-12 2004-06-24 Altana Pharma Ag Combination medicament
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
SE527069C2 (sv) 2003-06-19 2005-12-13 Mederio Ag Förfarande och anordning för administrering av läkemedelspulver
AU2003254429A1 (en) 2003-08-06 2005-02-25 Galephar M/F Advantageous combinations for inhalation of nacystelyn and bronchodilators
RU2006136025A (ru) * 2004-03-12 2008-04-20 Сипла Лимитед (In) Ингаляционные композиции
JP4621736B2 (ja) 2004-07-16 2011-01-26 アルミラル ソシエダツド アノニマ 粉末薬剤を投与するための吸入器、及びこの吸入器と共に使用するための粉末カートリッジシステム
CN101600469B (zh) 2006-12-22 2013-10-23 奥米罗有限公司 药粉吸入装置
CN101744792B (zh) * 2008-12-17 2013-04-17 张凯 氟替卡松丙酸酯和沙美特罗昔萘酸酯复方干粉吸入剂及其制备工艺
KR101926060B1 (ko) 2009-05-29 2018-12-06 펄 테라퓨틱스 인코포레이티드 활성제의 호흡기 전달용 조성물, 및 연관된 방법 및 시스템
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
SG11201507286QA (en) 2013-03-15 2015-10-29 Pearl Therapeutics Inc Methods and systems for conditioning of particulate crystalline materials
US20160158149A1 (en) * 2013-04-29 2016-06-09 Sanofi Sa Inhalable Pharmaceutical Compositions and the Inhaler Devices Containing Them

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2107715B (en) * 1981-10-19 1985-11-13 Glaxo Group Ltd Micronised beclomethasone dipropionate monohydrate and powder inhalation compositions containing it
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
FR2588474B1 (fr) * 1985-10-16 1987-11-27 Cird Compositions synergetiques anti-inflammatoires a base d'un corticosteroide et d'un beta agoniste

Also Published As

Publication number Publication date
DE19975040I2 (de) 2006-07-13
HK18695A (en) 1995-02-17
NZ235221A (en) 1992-11-25
SG166294G (en) 1995-06-16
CA2024916A1 (en) 1991-03-09
PH27594A (en) 1993-08-31
IT1241996B (it) 1994-02-02
DE69005951T2 (de) 1994-05-26
EP0416951A1 (en) 1991-03-13
NL990012I2 (nl) 1999-09-01
IT9048260A0 (it) 1990-09-07
IL95590A (en) 1996-06-18
FR2651677B1 (fr) 1993-08-06
CH680983A5 (en:Method) 1992-12-31
BE1003053A3 (fr) 1991-11-05
CH680983C9 (en:Method) 2008-08-15
JP3042867B2 (ja) 2000-05-22
DE69005951D1 (de) 1994-02-24
FR2651677A1 (fr) 1991-03-15
CA2024916C (en) 2002-07-09
IE65535B1 (en) 1995-11-01
EP0416951B1 (en) 1994-01-12
CH680983C1 (en:Method) 2008-06-25
ES2062392T3 (es) 1994-12-16
IT9048260A1 (it) 1992-03-07
IL95590A0 (en) 1991-09-16
ATE99941T1 (de) 1994-01-15
IE903256A1 (en) 1991-03-13
JPH03167120A (ja) 1991-07-19
NL990012I1 (nl) 1999-07-01
HU211272A9 (en) 1995-11-28
DK0416951T3 (da) 1994-02-14

Similar Documents

Publication Publication Date Title
LU90392I2 (fr) Une combination comprenant du salmeterol facultativement sous la forme d'un sel pharmaceutiquement acceptable y compris le 1-hydroxy-2-naphtoate (xinafoate) et le propionate de fluticasone
CA2093806A1 (en) Method of treating or preventing type 1 diabetes by oral administration of insulin
CA2123909A1 (en) New combination of formoterol and budesonide
DE69002718D1 (de) Medikamente.
BR0008699A (pt) Combinações de formoterol e furoato demometasona para asma
CY1105707T1 (el) Συνδυασμοι φορμοτερολης και ενος αλατος τριοτροπιου
GB8623557D0 (en) Therapeutic agents
CA2362539A1 (en) Fluorocarbon aerosol medicaments
ZA96779B (en) Calcitonin salmon analogues their preparation medicinal use and use as analytical agents
CA2038744A1 (en) Pharmaceutical composition containing slightly water-soluble drug
HUP0202525A2 (hu) Mofetil mikofenolát és PEG-IFN-alfa együttes alkalmazása, valamint az azokat tartalmazó gyógyszerkészítmények és kit
HUP0002533A2 (hu) Asztmaellenes gyógyszerhatóanyagok új kombinációja
MY111155A (en) Medicaments